Complement-dependent cytotoxicity (CDC)
The Complement-Dependent Cytotoxicity (CDC) Assay incorporates Human Serum or Autologous plasma to capture the activity of these monoclonal antibodies by evaluating their depletion results based on the quantification of live cells. Initial target quantification is evaluated by Flow Cytometry to correlate with the ex vivo activity.
Tubeandbracket
Native Blook Cell Populations

Human
Serum

Human Serum
Cytotoxic Drug Therapy
Plate Cytotoxic Drug

Hematological
Sample

Native Cell
Population

Drug Incubation
+ humanSerum

Cells Retrieval &
FCM Readout

CDC Assay:
Native Environment

003 CDC Rituximab & Alemtuzumab Assay
Hematological
Sample
Tubeandbracket
Native Cell Population
Native Blook Cell Populations
Drug Incubation + humanSerum
Drug Therapy

Human
Serum

Human Serum
Cytotoxic Drug Therapy
Cells Retrieval & FCM Readout
Plate Cytotoxic Drug
CDC Assay:
Native Environment
003 CDC Rituximab & Alemtuzumab Assay